enGene HoldingsENGN
ENGN
About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Employees: 57
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
21% more capital invested
Capital invested by funds: $228M [Q3] → $275M (+$47M) [Q4]
13% more funds holding
Funds holding: 30 [Q3] → 34 (+4) [Q4]
3.47% more ownership
Funds ownership: 77.55% [Q3] → 81.02% (+3.47%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
75%
upside
Avg. target
$23
476%
upside
High target
$34
752%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Morgan Stanley Jeffrey Hung 8% 1-year accuracy 2 / 26 met price target | 752%upside $34 | Overweight Maintained | 11 Mar 2025 |
HC Wainwright & Co. Andres Maldonado 14% 1-year accuracy 7 / 51 met price target | 527%upside $25 | Buy Reiterated | 11 Mar 2025 |
Piper Sandler Allison Bratzel 36% 1-year accuracy 4 / 11 met price target | 552%upside $26 | Overweight Initiated | 18 Feb 2025 |
UBS Colin Bristow 17% 1-year accuracy 2 / 12 met price target | 75%upside $7 | Neutral Downgraded | 14 Feb 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price.
Neutral
Business Wire
3 weeks ago
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e.
Neutral
Business Wire
1 month ago
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o.
Neutral
Business Wire
1 month ago
enGene to Participate in the Leerink Partners Global Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com a.
Positive
Seeking Alpha
1 month ago
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
Positive
Zacks Investment Research
2 months ago
Best Momentum Stocks to Buy for February 19th
NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.
Positive
Zacks Investment Research
2 months ago
New Strong Buy Stocks for February 19th
GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024.
Neutral
Business Wire
2 months ago
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced that Alex Nichols, Ph.D., Chief Strategy.
Neutral
Business Wire
2 months ago
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to.
Neutral
Business Wire
2 months ago
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced three poster presentations at the 2025.
Charts implemented using Lightweight Charts™